ArticleMarine drugs2014
New ikarugamycin derivatives with antifungal and antibacterial properties from Streptomyces zhaozhouensis.
Article in Marine drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Marine Microbes: A Source of Novel Antibiotics against Antimicrobial-resistant (AMR) Pathogens: A Systematic Review.Current drug targets · 2026Pooled it
- Pooled it
- Sustainable Biocatalytic Cascades: A Versatile Tool in the Synthesis of Natural Products With Therapeutic Potential.Chembiochem : a European journal of chemical biology · 2026Review
- Chlokamycins B-D: Chlorohydrin-Containing Polycyclic Tetramate Macrolactams with Cytotoxic Activity from the Marine Sponge-DerivedMarine drugs · 2026Article
- Mining Actinomycetes' Metabolomes and Genomes for Anti-Phytophthora infestans Compounds.Microbial biotechnology · 2025Article
- Chemical Diversity and Ecological Origins of Anti-MRSA Metabolites fromAntibiotics (Basel, Switzerland) · 2025Review
- Review
- Heterologous Expression and Optimization of Fermentation Conditions for Recombinant Ikarugamycin Production.Biotechnology and bioengineering · 2025Article
- Expanding Polycyclic Tetramate Macrolactam (PoTeM) Core Structure Diversity by Chemo-Enzymatic Synthesis and Bioengineering.Angewandte Chemie (International ed. in English) · 2025Article
- Enhancing Antifungal Drug Discovery Through Co-Culture with AntarcticInternational journal of molecular sciences · 2024Article
- New polycyclic tetramate macrolactams with antimycobacterial activity produced by marine-derived Streptomyces sp. KKMA-0239.The Journal of antibiotics · 2024Article
- Review
- MarineMarine drugs · 2024Review
- Anti-Candidal Marine Natural Products: A Review.Journal of fungi (Basel, Switzerland) · 2023Review
- Production of antibacterial compounds usingSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Article
- iChip-Inspired Isolation, Bioactivities and Dereplication ofMicroorganisms · 2022Article
- RhizosphericPlants (Basel, Switzerland) · 2022Article
- Ingestional Toxicity of Radiation-Dependent Metabolites of the Host Plant for the Pale Grass Blue Butterfly: A Mechanism of Field Effects of Radioactive Pollution in Fukushima.Life (Basel, Switzerland) · 2022Article
- Antifungal metabolites, their novel sources, and targets to combat drug resistance.Frontiers in microbiology · 2022Review
- Antimicrobial Profile of Actinomycin D Analogs Secreted by Egyptian DesertAntibiotics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A bioassay guided fractionation of the ethyl acetate extract from culture broths of the strain Streptomyces zhaozhouensis CA-185989 led to the isolation of three new polycyclic tetramic acid macrolactams (1-3) and four known compounds. All the new compounds were structurally related to the known Streptomyces metabolite ikarugamycin (4). Their structural elucidation was accomplished using a combination of electrospray-time of flight mass spectrometry (ESI-TOF MS) and 1D and 2D NMR analyses. Compounds 1-3 showed antifungal activity against Aspergillus fumigatus, Candida albicans and antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.